Literature DB >> 9137488

Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer.

N H Chow1, H S Liu, E I Lee, C J Chang, S H Chan, H L Cheng, T S Tzai, J S Lin.   

Abstract

UNLABELLED: The expression of epidermal growth factor receptor (EGFR) has been suggested to play an important role in the progression of bladder cancer through paracrine stimulation by epidermal growth factor in the urine. However, there is no information regarding the expression of EGFR and urinary ligand measurement in corresponding tumors in patients with bladder cancer.
MATERIALS AND METHODS: Paired analysis of urinary levels of epidermal growth factor (U-EGF) and the expression of EGFR was performed on 48 cases of bladder cancer. U-EGF test and EGFR status were correlated with clinicopathologic factors of bladder cancer, and compared for their prognostic value with a mean follow-up of 39.7 months.
RESULTS: U-EGF was inversely correlated with the intensity of EGFR expression (p = 0.04); while no substantial relationship was observed with other conventional prognostic indicators (p > 0.1, respectively). Multivariate analysis revealed that factors correlated with the risk of recurrence were EGFR status (p = 0.03) and histological grading (p = 0.05). An important indicator associated with poor patient survival was size of tumor at diagnosis (p = 0.03). DISCUSSION: Although measurement of U-EGF levels did not have any independent prognostic value, our data support the importance of urine EGF/urothelial EGFR interaction in the biological behavior of bladder cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9137488

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  26 in total

1.  Minimally invasive colorectal resection is associated with a rapid and sustained decrease in plasma levels of epidermal growth factor (EGF) in the colon cancer setting.

Authors:  Michael J Grieco; H M C Shantha Kumara; Raymond Baxter; Nadav Dujovny; Matthew F Kalady; Vesna Cekic; Martin Luchtefeld; Richard L Whelan
Journal:  Surg Endosc       Date:  2010-03-31       Impact factor: 4.584

Review 2.  Epidermal growth factor receptor and bladder cancer.

Authors:  A J Colquhoun; J K Mellon
Journal:  Postgrad Med J       Date:  2002-10       Impact factor: 2.401

3.  Optimal Role of the Nephrologist in the Intensive Care Unit.

Authors:  D J Askenazi; Michael Heung; Michael J Connor; Rajit K Basu; Jorge Cerdá; Kent Doi; Jay L Koyner; Azra Bihorac; Ladan Golestaneh; Anitha Vijayan; Mark D Okusa; Sarah Faubel
Journal:  Blood Purif       Date:  2016-12-03       Impact factor: 2.614

Review 4.  Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.

Authors:  Pravin T P Kaumaya; Kevin Chu Foy
Journal:  Future Oncol       Date:  2012-08       Impact factor: 3.404

5.  Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma.

Authors:  Jianhong Li; Cynthia L Jackson; Dongfang Yang; Lelia Noble; Michael Wheeler; Dolores MacKenzie; Temitope Adegun; Ali Amin
Journal:  Target Oncol       Date:  2014-10-08       Impact factor: 4.493

6.  Urothelial carcinomas: a focus on human epidermal receptors signaling.

Authors:  Petros D Grivas; Mark Day; Maha Hussain
Journal:  Am J Transl Res       Date:  2011-07-25       Impact factor: 4.060

7.  A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.

Authors:  Maha Hussain; Stephanie Daignault; Neeraj Agarwal; Petros D Grivas; Arlene O Siefker-Radtke; Igor Puzanov; Gary R MacVicar; Ellis Glenn Levine; Sandy Srinivas; Przemyslaw Twardowski; Mario A Eisenberger; David I Quinn; Ulka N Vaishampayan; Evan Y Yu; Scott Dawsey; Kathleen C Day; Mark L Day; Mahmoud Al-Hawary; David C Smith
Journal:  Cancer       Date:  2014-05-06       Impact factor: 6.860

Review 8.  Management of bladder cancer: current and emerging strategies.

Authors:  Neeraj Agarwal; Maha Hussain
Journal:  Drugs       Date:  2009-06-18       Impact factor: 9.546

Review 9.  Growth factors and receptors as prognostic markers in urothelial carcinoma.

Authors:  Peter C Black; Colin P N Dinney
Journal:  Curr Urol Rep       Date:  2008-01       Impact factor: 3.092

10.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.